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INTRODUCTION 
 Breast  carcinoma  has  a  major  impact  on  the  health  of women.  
Cancer  of  the  breast  is  the  most  common  cancer  among women  in  
many  regions  in  India  and  has  overtaken  cancer  cervix (1). Presently  
75,000  new  cases  occur  in  India  every  year. 
 Breast  cancer  survival  is  linked  to  early  detection  and timely  
appropriate  treatment .  Prognosis  is  related  to  a  variety  of clinical,  
pathological  and  molecular  features  which  includes  stage  of  the  
carcinoma,  histologic type,  grade  and  lymph  node  metastasis .  
Estrogen  and  progesterone  receptors  have, with  increasing  importance,  
influenced  the  management  of  this  malignancy(2).  
 With  an  established  positive  correlation  of  ER  and  PR  with 
the  degree  of  tumour  differentiation,  determination  of  ER  and   PR 
status  on  breast  biopsy  specimens,  prior  to  therapeutic  intervention  
is advocated  as a  standard  practice(3).  Survival  and  response  to  
hormone therapy  are  most  favourable  among  women  who  are  
receptor positive. 
 With  these  prognostic  implications,  the  need  for  accurate and  
precise  assessment  of  ER  and  PR  in  breast  carcinomas  is essential to 
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predict the response to hormone therapy.  Immunohistochemistry  is  the  
most  commonly used  and the  best method  of  testing  ER  and  PR  
status(4,16). 
 This  study  is  aimed  at  assessing  the  hormone  receptor status  
in  breast  carcinomas  and  to  correlate  this  reactivity  pattern with  
histologic  grade,  tumor  stage  and  lymph  node  metastasis. 
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AIMS AND OBJECTIVES 
1. To assess the clinical stage using American Joint Committee 
Cancer staging system. 
2. To grade the the breast tumors based on Nottinghams modification 
of Bloom & Richardson  grading  system.   
3. To assess ER, PR status of breast carcinomas by 
immunohistochemistry using Quick score. 
4. To study the correlation between ER, PR status and other 
prognostic indicators of  breast  cancer. 
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REVIEW OF LITERATURE 
 Breast is a modified sweat gland resting on pectoral muscle. It 
extends from 2nd to 6th rib and from sternal edge to near the mid axillary 
line. 
 Breast carcinoma is becoming the most common malignant tumor 
in women. It causes 3,76,000 deaths in women in a year worldwide and 
every year 9,00,000 new cases are diagnosed. 
 There is a sharp increase in the detection of breast carcinoma, 
owing to widespread use of mammography. However, the mortality from 
breast carcinoma is beginning to fall, presumably because of earlier 
diagnosis and improved therapy. 
HISTOLOGY 
 The functional unit of  breast is lobule. There are numerous lobules 
within each breast. Lobules consist of variable number of blind ended 
terminal ductules alternatively called acini which is lined by double 
layered epithelium- outer flattened myoepithelial cell, inner cuboidal 
epithelial cells with secretory function. 
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 The acini drain into terminal duct. Each terminal duct and its acini 
are together referred to as Terminal Duct Lobular Unit(TDLU). The 
terminal duct drains into sub segmental, segmental ducts and finally into 
lactiferous duct. There are 15-20 lactiferous ducts which open into the 
nipple. Immediately below the nipple, the lactiferous duct dilates to form 
lactiferous sinus. 
RISK FACTORS  
 The frequency of the disease has prompted an intensive study of 
risk factors. The common denominator for these factors is strong and 
prolonged estrogen stimulation operating on a genetically susceptible 
background. 
1. AGE: Breast cancer is rarely found before the age of 25 years. 
70% occur in women over 50 years. Incidence rises throughout a 
woman’s life. 
2. REPRODUCTIVE & MENSTRUAL HISTORY: Early 
menarche, late menopause, nulliparity, women over age 35 at first 
pregnancy have increased risk because of  high estrogen 
stimulation(9). 
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3. FAMILY HISTORY: Women who have first degree relatives 
with breast carcinoma have increased risk (5), probably because of 
mutation in BRCA1 and BRCA2. 
4. PRENEOPLASTIC CONDITIONS: Atypical hyperplasias and 
florid epitheliosis are associated with increased risk (8). 
5. RACE & SOCIOECONOMIC GROUP: Incidence of breast 
carcinoma is high among high socio-economic group.   
 Additional risk factors are also recognised, but there is a lack of 
definitive correlation. The additional risk factors includes the following, 
1. ESTROGEN EXPOSURE: Hormone replacement therapy and 
use of oral contraceptive pills are associated with increased risk of 
breast cancer. Oophorectomy reduces the risk of breast cancer by 
75%(6,7). 
2. RADIATION EXPOSURE: Therapeutic radiation and atom 
bomb survivors have increased risk. 
3. BREAST FEEDING: The longer the women breast feed, the 
greater is the reduction in the risk of breast cancer. 
4. DIET: High fat diet and obesity carry increased risk.  
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HISTOLOGICAL CLASSIFICATION OF TUMORS OF BREAST 
BY WHO 
Epithelial tumors 
• Invasive ductal carcinoma, not otherwise specified 
¾ Mixed type carcinoma 
¾ Pleomorphic carcinoma 
¾ Carcinoma with osteoclastic giant cells 
¾ Carcinoma with choriocarcinomatous features 
¾ Carcinoma with melanotic features 
• Invasive lobular carcinoma 
• Tubular carcinoma 
• Invasive cribriform carcinoma 
• Medullary carcinoma 
• Mucinous carcinoma and other tumors with abundant mucin 
¾ Mucinous carcinoma 
¾ Cystadenocarcinoma and columnar cell mucinous 
carcinoma 
¾ Signet ring cell carcinoma 
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• Neuroendocrine tumors 
¾ Solid neuroendocrine carcinoma 
¾ Atypical carcinoid tumor 
¾ Small cell/ Oat cell carcinoma 
¾ Large cell neuroendocrine carcinoma 
• Invasive papillary carcinoma 
• Invasive micropapillary carcinoma 
• Apocrine carcinoma 
• Metaplastic carcinomas 
¾ Pure epithelial metaplastic carcinomas 
 Squamous cell carcinoma 
 Adenocarcinoma with spindle cell metaplasia 
 Adenosquamous carcinoma 
 Mucoepidermoid carcinoma 
¾ Mixed epithelial / mesenchymal metaplastic 
carcinomas 
• Lipid rich carcinoma 
• Secretory carcinoma 
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• Oncocytic carcinoma 
• Adenoid cystic carcinoma 
• Acinic cell carcinoma 
• Glycogen-rich clear cell carcinoma 
• Sebaceous carcinoma 
• Inflammatory carcinoma 
• Lobular neoplasia 
¾ Lobular carcinoma in situ 
• Intraductal proliferative lesions 
¾ Usual ductal hyperplasia 
¾ Flat epithelial atypia 
¾ Atypical ductal hyperplasia 
¾ Ductal carcinoma in situ 
• Microinvasive carcinoma 
• Intraductal papillary neoplasms 
¾ Central papilloma 
¾ Peripheral papilloma 
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¾ Atypical papilloma 
¾ Intraductal papillary carcinoma 
¾ Intracystic papillary carcinoma 
• Benign epithelial proliferations 
¾ Adenosis including variants 
 Sclerosing adenosis 
 Apocrine adenosis 
 Blunt duct adenosis 
 Microglandular adenosis 
 Adenomyoepithelial adenosis 
 Radial scar/ complex sclerosing lesion 
¾ Adenomas 
 Tubular adenoma 
 Lactating adenoma 
 Apocrine adenoma 
 Pleomorphic adenoma 
 Ductal adenoma 
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Myoepithelial lesions  
• Myoepitheliosis 
• Adenomyoepithelial adenosis 
• Adenomyoepithelioma 
• Malignant myoepithelioma 
Mesenchymal tumors 
• Hemangioma 
• Angiomatosis 
• Hemangiopericytoma 
• Pseudoangimatous stromal hyperplasia 
• Myofibroblastoma 
• Fibromatosis(aggressive) 
• Inflammatory myofibroblastic tumor 
• Lipoma 
¾ Angiolipoma 
• Granular cell tumor 
• Neurofibroma 
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• Schwannoma 
• Angisarcoma 
• Liposarcoma 
• Rhabdomyosarcoma 
• Osteosarcoma 
• Leiomyoma 
• Leiomyosarcoma 
• Fibroepithelial tumors 
• Fibroadenoma 
• Phyllodes tumor 
¾ Benign 
¾ Borderline 
¾ Malignant 
• Periductal stromal sarcoma, low grade 
• Mammary hamartoma 
Tumors of the nipple 
• Nipple adenoma 
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• Syringomatous adenoma 
• Paget's disease of the nipple 
Malignant lymphoma 
• Diffuse large B-cell lymphoma 
• Burkitt’s lymphoma 
• Extranodal marginal zone B-cell lymphoma of MALT type 
• Follicular lymphoma 
Metastatic tumors 
Tumors of the male breast 
• Gynaecomastia 
• Carcinoma 
¾ Invasive 
¾ In situ 
 Almost all breast malignancies are adenocarcinomas, all other 
types making up fewer than 5% of the total. 
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 Carcinomas are divided into in situ and invasive. Invasive 
carcinoma has invaded beyond the basement membrane into the stroma. 
All carcinomas are thought to arise from terminal duct lobular unit. 
 WHO classification is based on the growth pattern and cytologic 
features and does not imply histogenesis or site of origin within 
mammary duct system. 
 The most common histologic type of invasive breast cancer by far 
is invasive ductal carcinoma- not otherwise specified(11). 
INVASIVE DUCTAL CARCINOMA- NOS TYPE: 
 Rosen(1975) accounts that this type constitutes 65-80% of 
mammary carcinomas.  
 Microscopically, architectural arrangement may be in cords, 
clusters and trabeculae while some are characterised by predominantly 
solid or syncytial infiltrative pattern(13). 
 In a study conducted by Paul Peter Rosen et al, these carcinomas 
show 70-80% ER, PR positivity(12). According to Lakhmini K.B. 
Mudduwa the prevalence of hormone receptor positive breast cancer in 
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Asian countries has found to be lower than western world where more 
than 50% tumors express hormone receptors(64). 
 Pleomorphic carcinoma is a rare variant of high grade ductal 
carcinoma -NOS characterised by pleomorphic and bizarre giant cells in 
more than 50% of tumor cells in a background of adenocarcinoma(13,14). 
 In a study conducted by Ellis I O et al, 10 year survival rate of this 
tumor ranges from 33-48%(28). 
INVASIVE LOBULAR CARCINOMA 
 The classical form of infiltrating lobular carcinoma was first 
described by Foote & Stewart(15). 
 In a study conducted by Grazio Arpino et al, this  type represents 
4.9-15% of all invasive breast carcinomas(31). They are frequently 
bilateral and multicentric when compared with other subtypes(14). 
 Microscopically, cells are round or oval with eccentrically placed 
nuclei with small nucleoli and small amount of cytoplasm. They have 
characteristic Indian file or targetoid pattern. 
 Dixan.J.M. conducted receptor assay that reveals ER, PR positvity 
in 67-92% of cases(12).  
 16
 It has a clinical outcome similar to IDC-NOS type. 10-year 
survival rate is 54%(27,28). 
TUBULAR CARCINOMA: 
 Tubular carcinoma is usually smaller than 2cm and has two 
morphological types, ‘pure type’ with stellate nature and sclerosing type 
with more diffuse ill-defined nature. 
 Microscopically, it has irregularly arranged tubules lined by single 
layer of epithelial cells with little pleomorphism and low mitotic rate. The 
tubules are characteristically angulated and have open glandular lumina. 
 Pure tubular carcinomas have an excellent prognosis(17). 10-year 
survival rate is 90%(28). 
MUCINOUS CARCINOMA: 
 WHO defines it as “large amount of extracellular mucin sufficient 
to be visible both grossly and microscopically surrounding the tumor 
cells”(10). 
 Microscopically, the tumor consists of small islands or clusters of 
epithelial cells floating in lakes of extracellular mucin divided by delicate 
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fibrous septae. The lakes of mucin are positive for PAS and mucicarmine 
stain. 
 ER, PR positivity ranges from 73-95%(12).These tumors carry a 
very good prognosis with 10-year survival data varying between 68 and 
90%(17,28). 
MEDULLARY CARCINOMA: 
 Grossly the tumor appears as well-circumscribed, soft and fleshy. 
WHO defines it as “well circumscribed carcinoma composed of poorly 
differentiated cells with scant stroma and prominent lymphocytic 
infiltration”. They carry a good prognosis with 10-year survival rate of 
84%(12,30). Immunohistochemical studies of hormone expression 
conducted by Ponsky et al were negative(18,19). 
PAPILLARY CARCINOMA:    
 Diagnosed predominantly in postmenopausal patients. 
Microscopically, circumscribed, show delicate or blunt papillae with 
focal solid areas of tumor growth. DCIS is present in >75% of cases and 
usually has papillary pattern(29). They have an excellent 
prognosis(27,28). 
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 In a study conducted by Zekioglu et al hormone receptor positivity 
is seen in 89% of cases (24). 
METAPLASTIC CARCINOMA: 
 WHO defines it as “a heterogenous group of neoplasms with 
spindle cells, squamous cells or with mesenchymal differentiation. 
Extensive sampling of metaplastic tumors should be done to identify 
carcinomatous foci and distinguish them from true sarcomas because of 
differences in biologic behaviour and response to therapy. 
 It behaves as a highly malignant tumor with early recurrence and 
poor survival(23,28). 
 According to Tzu-Chieh Chao et al, hormone receptors were 
negative in majority of the cases (22). 
NEUROENDOCRINE CARCINOMA: 
 WHO defines this type as a carcinoma with neuroendocrine marker 
positivity noted in more than 50% of the cell population(10,20). This type 
has an infiltrative morphology with component cells arranged in nests, 
sheets or trabecular formation and peripheral palisading of cell 
groups((13,14,60). 
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 In a study conducted by Niremudi et al, 55-65% showed ER, PR 
positivity. 
PROGNOSTIC AND PREDICTIVE FACTORS 
 Prognosis is determined by the pathologic examination of the 
primary carcinoma and the axillary lymph nodes. Major  prognostic 
factors  are  the  strongest  predictors  of  death  from  breast  carcinoma 
and are incorporated into the American Joint Committee cancer(AJCC) 
staging system. Predictive factors are used to determine the likelihood of 
response to a particular therapy. Major prognostic and predictive factors 
are: 
1. TUMOR SIZE:  
 The diameter of the primary tumor shows a good correlation with 
the incidence of nodal metastases and with the survival rate. This easier, 
quicker and cheaply determined parameter has been found to be one of 
the strongest predictors of dissemination and rate of relapse in node 
negative breast carcinoma. Women with node negative carcinomas, 
which are less than 1cm in diameter, have a prognosis approaching that of 
women without treatment  approximately 90% (14,33). 
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 According to Michaelson et al, for correlation with prognosis, the 
size of tumor should  be assessed only on pathological specimens, as 
clinical measurements may be inaccurate (36). 
2. EXCISION MARGINS: 
 Microscopic examination of the excision margins is usually 
undertaken to assess the adequacy of surgical excision and hence the 
probability of recurrence. According to Swanson et al and Frazier et al ,it 
has been found that when the tumor reaches the excision margins, there is 
a significantly increased risk of local recurrence and distant 
metastasis.(37,38). 
3. HISTOLOGIC SUBTYPE: 
 30-year survival rate of women with special type of carcinomas 
(tubular, mucinous, medullary, papillary)is greater than 60% compared 
with less than 20% for women with carcinomas of no specific type(27). 
4. VASCULAR  INVASION: 
 Tumors stimulate the growth of host blood vessels (angiogenesis). 
Tumor emboli are mainly seen within thin walled channels. Since it is 
almost impossible to determine whether such spaces are lymphatics or 
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venules, the broad term vascular invasion is used(39). 
Immunohistochemistry for  endothelial markers can differentiate  blood 
vessel and lymph vessel invasion(41).  
 There is significant relationship between the presence of vascular 
invasion and prognosis as judged by local recurrence and survival(40).  
5. LYMPH NODE STAGE: 
 Axillary lymph node is the most important prognostic factor for 
invasive carcinoma in the absence of distant metastasis(43). The clinical 
assessment of nodal involvement is very inaccurate with both false 
positive (as in palpable reactive nodes) and false negative findings (as 
with small metastatic deposits). Hence biopsy is required for accurate 
assessment. 
 Numerous studies have shown that  patients who have 
histologically confirmed loco-regional lymph node involvement  have a 
poorer prognosis than those without nodal involvement(43). According to 
Veronesi et al, 10-year survival rate is reduced from 75% for patients 
with no lymph node involvement to 25-30% for those with lymph node 
metastasis(44). 
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 Prognosis is more likely related to the number of nodes involved 
rather than size of the deposit. 
 For prognostic purpose, the best grouping seems to be the 
following 
1- negative nodes 
2- one to three positive nodes 
3- four or more positive nodes 
 With no nodal involvement, the 10-year disease-free survival rate 
is close to 70 to 80%, the rate falls to 35-40% with one to three positive 
nodes and 10-15% in the presence of more than ten positive nodes(33). 
 The level of nodal involvement also provides useful prognostic 
information(44). Metastasis is not only a marker of diagnosis at a latter 
point in the history of breast cancer, but also a marker of aggressive 
phenotype(42). 
6. HISTOLOGICAL GRADE: 
 Most commonly used grading system to assess the degree of 
differentiation is Nottingham modification of the Bloom-Richardson 
system. 
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 The grading criteria for this system are: 
a. Tubule formation: 
 Score1 - tubular formation in >75% of the tumor 
 Score2 - tubular formation in 10-75% of the tumor 
 Score3 - tubular formation in <10%  of the tumor 
b. Nuclear pleomorphism: 
 Score1 - nuclei with minimal variation in size and shape 
 Score2 - nuclei with moderate variation in size and shape 
 Score3 - nuclei with marked variation in size and shape 
c. Mitotic count: 
 Mitotic figures are to be counted only at the periphery of the tumor. 
Counting should begin in the most mitotically active area; 10 high power 
fields are to be counted in the same area. 
 Score1 -  0-9 mitoses/10 hpf 
 Score2 - 10-19 mitoses/10hpf 
 Score3 - 20/> mitoses/10 hpf 
Allocation of grade: 
 Scores are added together and allocated as  
 Score3-5              grade1 
 Score6-7              grade2 
 Score8-9              grade3 
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 According to Enad.A.Rakha et al, histologic grade as assessed by 
Nottingham grading system, provides a strong predictor of outcome in 
patients with invasive breast cancer (34). 
7. NOTTINGHAM  PROGNOSTIC  INDEX: 
 A study conducted by Galea et al showed a significant relationship 
of  prognosis with size, grade and lymph node metastasis (45). 
 Using the coefficients of significance for these factors, an index 
predicting survival – Nottingham prognostic index is calculated (NPI). 
 NPI=0.2x tumor size (in cm)+ lymph node stage(1-3)+ histological 
grade (1-3) 
 NPI SCORE PROGNOSIS 
 <3.4 good prognosis 
 3.4 - 5.4 moderate prognosis 
 >5.4 poor prognosis 
 It is a powerful and reproducible method of assessing prognosis 
and is the only integrated index which has been confirmed in prospective 
studies (46). 
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8. TNM STAGING: 
 The revised TNM staging for breast cancer, as approved by the 
AJCC is 
PRIMARY TUMOUR (T) : 
 Tx : Primary tumour cannot be assessed 
 T0 : No evidence of primary tumour 
 Tis : DCIS, LCIS, Paget’s disease of nipple with no tumour. 
 T1 : 
  T1mic : Microinvasion < 0.1 cm in greatest dimension. 
  T1a : Tumour more than 0.1 cm but < 0.5cm. 
  T1b : Tumour > 0.5cm but < 1 cm 
  T1c : Tumour 1-2 cms. 
 T2 : Tumour > 2cm but < 5 cms in greatest dimension 
 T3 : Tumour > 5 cms in greatest dimension 
 T4 : Tumour of any size 
   T4a : Extension to chest wall 
   T4b : Skin involvement (Peau d’orange, Ulcer, Satellite 
nodules ) 
   T4c :  Both T4a and T4b. 
   T4d : Inflammatory carcinoma. 
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REGIONAL LYMPHNODE (N) 
 Nx : Regional LN cannot be assessed (Eg. Previously removed) 
 N0 : No regional LN 
 N1 : Metastasis in mobile ipsilateral axillary LN (s). 
 N2a : Ipsilateral matted or fixed LNs. 
 N2b : Clinically apparent ipsilateral internal mammary nodes 
and in the absence of clinically evident axillary LNs. 
 N3a : Metastasis in ipsilateral axillary nodes and ipsilateral 
infraclavicular lymphnode. 
 N3b : Axillary LNs + Ipsilateral internal mammary LN(s) 
 N3c : Metastasis in ipsilateral supraclavicular LN (s). 
Pathologic classification 
 pNX : Regional lymph nodes cannot be assessed (eg., not 
removed for pathologic study or removed previously) 
 pN0 : No regional lymph node metastasis 
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 pN1 : Metastasis to movable ipsilateral axillary lymph node(s) 
 pN1a : Only micrometastasis (none >0.2 cm) 
 pN1b : Metastasis to lymph node(s), any larger than 0.2cm 
 pN1bi : Metastasis in 1-3 lymph nodes, any larger than 0.2 cm 
and all smaller than 2 cm in greatest dimension 
 pN1bii : Metastasis to 4 or more lymph nodes, any larger than 
0.2 cm and all smaller than 2 cm in greatest dimension 
 pN1biii : Extension of tumor beyond the capsule of a lymph node 
metastasis, smaller than 2 cm in greatest dimension 
 pN1biv : Metastasis to a lymph node 2 cm or larger in greatest 
dimension 
 pN2 : Metastasis to ipsilateral axillary lymph node(s) fixed to 
each other or to other structures 
 pN3 : Metastasis to ipsilateral internal mammary lymph 
node(s) 
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METASTASIS 
 M0 : No distant metastasis 
 M1 : Distant Metastasis 
TNM STAGE GROUPING 
 Stage I : T1 N0 M0 
 Stage IIa : T1 N1 M0 
   T2 N0 M0 
 Stage II b : T2 N1 M0 
   T3 N0 M0 
 Stage IIIa : T0 N2 M0 
   T1 N2 M0 
   T2 N2 M0 
   T3 N1 M0 
   T3 N2 M0 
 Stage IIIb : T4 N0 M0 
   T4 N1 M0 
   T4 N2 M0 
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 Stage IIIc : Any T N3 M0 
 Stage IV : Any T Any N M1 
9. HORMONE RECEPTOR: 
 Women with estrogen and progesterone receptor positive cancer 
have  better prognosis than do women with hormone receptor negative 
carcinomas. The evaluation of hormone receptors is very valuable to 
predict response to hormone therapy(47,48,49). 
10. Her-2/neu: 
 It is a transmembrane glycoprotein involved in cell growth control. 
Over expression of Her-2 neu is associated with poor prognosis(47,48,49). 
11. PROLIFERATION RATE: 
           Proliferation can be measured by flow cytometry, by thymidine 
labelling index, by mitotic counts or by immunohistochemical detection 
of cellular proteins produced during cell cycle. Tumors with high 
proliferation rate have the worst prognosis(48,49). 
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IMMUNOHISTOCHEMISTRY 
 Immunohistochemistry is a method based on the selective binding 
of specific immunologic reagents to specific antigenic determinants on a 
cell. 
 ANTIGEN: Any foreign material that may enter the body and 
trigger the mechanism of immune response, that results in the production 
of antibodies. 
 ANTIBODY: Substances produced in response to an antigenic 
stimulus. 
 Immunohistochemistry is used to determine expression of 
particular antigen and its microanatomic location in the tissue. IHC uses 
antibodies to distinguish the antigenic differences between the cells. 
These differences identify the lineage of cell population and define 
biologically distinct population of cells within the same lineage. 
 Immunohistochemistry  was started in 1940 by Coons for frozen 
sections. 
 In 1966, Pierce modified it and used for paraffin sections. Antigen 
retrieval technique was introduced by Shi in 1991. Antigen retrieval 
 31
technique is a simple method that involves heating paraffin processed 
sections at high temperatures before IHC staining.  
 The use of antibody in immunohistochemistry depends on the 
sensitivity and specificity of antigen-antibody reaction and the 
Hybridoma technique  provides limitless source of highly specific 
antibodies. 
BLOCKING NON-SPECIFIC BACKGROUND STAINING: 
 Background staining is due to either non specific binding or 
presence of endogenous enzymes. Non-specific binding with polyclonal 
primary anrtibody is minimised by pre-incubating sections with serum 
from same species on optimal working dilution. 
 Endogenous enzymes such as peroxidase seen in normal and 
neoplastic tissues is abolished by peroxidase blocking or by using 
alternate systems such as immunogold technique. 
 Methods suggested to overcome endogenous activity include 
incubation in methanol containing 0.5% hydrogen peroxide for 10 
minutes at room temperature. 
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DETECTION  SYSTEMS: 
 Antibodies are labelled or flagged by some method to permit 
visualisation – these include fluorescent substances, heavy metals or 
enzymes. 
 Enzymes are the most widely used labels in immunohistochemistry 
and incubation with a chromogen using a standard histochemical method 
produces a stable coloured end product suitable for light microscopy. 
METHODS: 
DIRECT LABELLING METHOD: 
 Antibody is attached with a label by chemical means and directly 
applied to tissue sections. The advantage of this method is that they are 
simple to use. The main disadvantage is that the sensitivity is low. 
INDIRECT LABELLING METHOD: 
 Enzymes are labelled with secondary antibody, which is produced 
against primary antibody. This technique is more sensitive. 
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AVIDIN BIOTIN CONJUGATE METHOD: 
 In this technique primary antibody is added followed by 
biotinylated secondary antibody and next by preformed complexes of 
Avidin and Biotin horse radish peroxidase conjugate. This is also more 
specific.  
BIOTIN STREPTAVIDIN METHOD:  
 Modification  of Avidin  biotin  with  streptavidin being  used  
instead  of Avidin. Advantage  is less non specific background staining.  
IMMUNOGOLD  WITH  SILVER  ENHANCEMENT : 
 It can be used in both  direct and indirect methods  and  has found 
wide  image in  ultrastructural immuno location. Gold particles  enhanced 
by addition  of several layers of metallic sliver. This technique  may  
represent the  most sensitive and effective light microscopy 
immunohistochemical method  currently available.  
 Tissue for  IHC undergo  fixation,  dehydration  and paraffin 
embedding.  
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FIXATION  
 This is a critical step  as preservation of morphology is essential  
for interpretation of IHC. 10% buffered  neutral formalin is commonly 
used.  The disadvantage of masking antigens during fixation can be over 
come by antigen retrieval technique.  
 According to  Elizabeth et al ,  biopsies fixed  for  intervals  shorter 
than  6 hours  or longer than  72 hours,  sample where fixation delayed 
for more than one hour  may not give proper results (63).  
ANTIGEN RETRIEVAL  
 This procedure involves unmasking of the antigens. The following 
technique can be used.  
 1. Proteolytic  Enzyme  digestion  
 2. Microwave antigen retrieval   
 3. Pressure cooker antigen retrieval  
 4. Microwave and trypsin antigen retrieval  
 Care  should be taken  not to allow the section to dry after heating, 
as this destroys  antigenicity. Damage of nuclear details is seen in poorly  
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fixed tissues.  Fibres and  fatty tissues  tend  to detach from the slides 
while heating.  
CONTROLS  
 Use of control tissue is essential in  hormone receptor assays.  
Ideally, the test block should include normal breast  lobules  and  ducts to 
provide an internal control  population of cells, since a proportion  of 
these should show positive  reactivity. Use of internal  control cells  in 
this fashion  protects against the  effects of  poor fixation.  
HORMONE RECEPTOR  
 ER and PR are  dimeric,  gene - regulatory  proteins. Estrogen and 
progesterone are well established endocrine  steroid  regulators  that 
modulate  multiple aspects of mammary gland pathology. These two 
hormones work together  to direct  mammary  epithelial growth,  
differentiation and survival.  Although  both steroids  are commonly 
thought to be of primary importance for   tumours arising in the 
reproductively competent  years, between puberty  and menopause, local 
aromatization of adrenal androgens provides  additional estrogens  in the 
postmenopausal  years.  ER  and PR  belong to  super family proteins  
 36
whose  function  is to control the transcription of the  receptor of the 
cellular genes.  
 Estrogen and Progesterone receptor act through their  nuclear 
receptors to modulate  transcription  of target genes  (54).  
ESTROGEN RECEPTORS  
 ER may exist either in homodimeric  or hetero dimeric species,  
composed of  alpha  and beta receptors  acting  as  hormone dependent  
transcriptional regulators (55). ER alpha  is of key importance  in  
mammary  ductal elongation of puberty.  PR  and ER beta  appears to be 
more involved with  lactational  differentiation of the lobules (56).     
 Over expression of  ER alpha  is a well  established prognostic  
factor  in breast  cancer patients.  Generally  ER alpha positive cancers  
are associated with  slow tumour growth ,  lower  histology  grade,  DNA 
diploidy and thus  a better over all prognosis.  
 Estrogen receptors are regarded as  cytoplasmic receptors  in 
unliganded state. Since  they are  steroid  receptors, they do not  require  
membrane bound  receptors  for their  activation.  During activation  
estrogen  receptor rapidly diffuses  into the cytoplasm,  it migrates from  
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cytosol to nucleus,  then dimerisation of the receptor occurs  and 
subsequently  it binds into  hormone response  elements.  
PROGESTERONE RECEPTORS  
 PR is a heterodimeric  protein  with A and B  subunits.  Over 
expression of PR  indicates that the ER  pathway  is intact,  even if the 
tumour is reported as ER negative . 
 Hormone  receptors  are  well established  bio markers in breast 
carcinoma  and their assessment  helps in predicting  the response to 
endocrine therapy. 
SCORING SYSTEM  
 Estrogen and progesterone  receptors express  nuclear  positivity.  
Different scoring systems  are available and  includes  measurements  of  
intensity of staining  or percentage of positive cells or  a combination of 
the two.  
1. Quick Score  
 Assigns values to both intensity  and proportion of staining (50).  
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 Score for proportion staining  
  0   -  No nuclear  staining  
                    1  -  < 1%  nuclear staining  
  2  - 1 - 10% nuclear staining  
  3  -   11 - 33% nuclear  staining  
  4  -  34 - 66% nuclear staining  
  5  -  67 - 100% nuclear staining  
Score for staining intensity 
  0 - No staining  
  1 - Weak staining  
  2 - Moderate staining  
  3 - Strong  staining  
 This comes to a  maximum score of  8.   
 There are  many scoring  system  but Quick score,  which considers  
both proportion of cells and  intensity of staining  is used by  many 
laboratories.  According to  Leake R.  Barnes  et al., (50) , the results 
obtained from  Quick score correlates well with the biochemical assays  
and provides significant  predictive  and prognostic  information.  
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 In a study  conducted by  Thusharie Liyanage, the Quick score 
appears as  reliable scoring system at the therapeutic decision making 
level and a substantial to almost  perfect inter observer agreement was 
seen in assigning an over all scoring  (51).  
2. H Score : 
         This score is based on the percentage of  nuclei that  stain  and the 
intensity of the staining reaction i.e.  based on  the summation of 
proportion of tumour cells showing  different  degrees of  reactivity.  
Score :  
 0 - No reactivity  
 1 - Weak reaction  
 2 - Moderate reaction  
 3 - Strong reaction  
 This would give a maximum score of 300, if 100 percent  of 
tumour cells  shows strong  reactivity.  
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3. Fractionated score (F score)  
 Six  point  score by  estimating  percentage of positive staining 
tumour cells ( 52).  
Scoring  
 0 - None  
 1 - 1 - 10%  
 2  - 11 - 30%  
 3 - 31 - 50% 
 4 - 51 - 70% 
 5 - 71 - 100%  
 A percentage of 10% (i.e F score = 1)  is chosen  as cut-off value to   
dichotomise the results into  positive versus negative. 
4. J - Score  
  Evaluates only  positive cell rate  without taking the  staining 
intensity  into account (53). 
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Scoring Criteria  
 0 - No stained cells  
 1 - Stained cells  < 1%  
 2 - Stained cells 1 - 10%  
 3 - Stained cells > 10%  
Final decision  on  hormone  receptor status  
 Score  0  -       Negative   
 Score 1 & 2  -       Uncertain ( Equivocal)  
 Score 3 -        Positive  
5. Allred score  
 Hormone receptor expression was  scored by  assigning  proportion 
score  and  intensity  scores(57).  
Proportion score  
 0 - None  
 1 - < 1/100 
 2 - 1/100 to 1/10 
 3  - 1/10 to 1/3 
 4 - 1/3 to 2/3 
 5 - > 2/3  
 42
Intensity  score  
 0 - None 
 1 - Weak  
 2 - Intermediate  
 3 - Strong  
 The proportion and intensity scores  were then added  to obtain a 
total score,  which ranges from  0 - 8.   
Total  Score    
 0 - 2    Negative  
 3 - 8   Positive  
SIGNIFICANCE OF  ER, PR  STATUS ASSESSMENT  IN 
BREAST CARCINOMAS  
 Women with  hormone receptor positive cancers have a slightly 
better prognosis than do women with  hormone receptor negative 
carcinomas.  The evaluation of hormone  receptors is more valuable to 
predict response to therapy.  
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 Patients with  hormone receptor positive tumours benefit from  
adjuvant tamoxifen treatment, regardless of  nodal status, menopausal 
status  and age. Both recurrence free survival and breast cancer survival 
are improved (62).  
       According to  Osborne et al.,  patient with  ER + and PR +  tumours 
have  78% response, those with ER + PR - have 34% response,  those 
with ER -ve PR +  have 45% response  and ER - PR -  tumours  have 
10% response to hormone therapy (65).  
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MATERIALS AND METHODS 
 A total of 73 mastectomy specimens  were received in the 
Department of Pathology, Kilpauk Medical College,  from the 
Department of Surgery between  July 2008  and  September 2010.  
 A detailed history regarding age, parity, socio economic status, 
family history  and menstrual history were reviewed  in  all cases.  
Inclusion criteria :  
 All female patients who underwent  mastectomy  irrespective of 
age and proved to be  malignant histologically were included for study.  
Exclusion  criteria : 
 Excision and incision  biopsies , proven to be  malignant 
histologically, were not  included in the study.  
 Of the 73 cases, ER, PR study was done for 55 cases.  All the 
mastectomy specimens received were  properly sliced  and  fixed in  10% 
formalin for 18 - 24 hours.  Detailed gross examination pertaining to  
over all size of the specimen,  nipple and areola,  margin status and nodal 
status were carefully studied.  
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 Histological grading was done by  modified Bloom and Richardson 
scoring system.  
 Representative samples are taken from tumour, margins, nipple and 
areola  and lymph nodes. The tissues were processed  in various  grades  
of alcohol and xylol  using  automated  histokinette. Paraffin  blocks were 
prepared  and  sections of  5micron thickness were cut in  microtome  
using  disposable blades  and stained with  hematoxylin and eosin. 
Suitable blocks were  chosen for IHC.  
Immunohistochemistry  
 Sections for Immunohistochemistry  were also cut in  microtome  
using   disposable blades.  Slides coated with  chrome  alum  were  used.  
Sections were  subjected to  antigen retrieval  using  pressure cooker 
technique using  citrate retrieval solution (pH 6) and then treated by 
Horse Radish  Peroxidase (HRP) polymer  techniques.  
Methodology 
 Coated slides  after antigen  retrieval  were taken through following 
stages.  
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1. Treatment with  peroxidase  block for inhibiting  endogenous  
peroxidases  in the tissue  for  5 minutes.  
2. Washed twice  in TRIS buffer  for  5 minutes . 
3. Application of  power block for  blocking  non-specific  
antigen- antibody  reaction  for 5 minutes.  
4. Washed twice in TRIS buffer  for  5 minutes.  
5. Application  of primary antibody  for  60 minutes.  
6.  Washed twice  in TRIS buffer  for  5 minutes.  
7. Application of secondary antibody with the tagged  Horse  
Radish Peroxidase  enzyme for 30 minutes.  
8. Washed twice in TRIS buffer  for  5 minutes.  
9. Application of super enhancer for 30 minutes  which  
enhances   the final reaction product  by increasing the 
sensitivity of antigen - antibody reaction.  
10. Washed twice in TRIS buffer  for  5 minutes.  
11. Application of DAB ( Diamino benzidine)  chromogen for  5 
minutes  - this is cleaved  by  enzyme  to give coloured 
product at the antigen sides.  
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12. Washed in distilled water for  5 minutes.  
13. Slides are counter stained with  hematoxylin.  
14. Air dried  and mounted with DPX .  
Scoring system  
 Scoring done by  Quick Score System  
 Score for proportion  staining  
  0   -  No nuclear  staining  
  1  -  < 1%  nuclear staining  
  2  - 1 - 10% nuclear staining  
  3  -   11 - 33% nuclear  staining  
  4  -  34 - 66% nuclear staining  
  5  -  67 - 100% nuclear staining  
 Score for staining intensity 
  0 - No staining  
  1 - Weak staining  
  2 - Moderate staining  
  3 - Strong  staining  
 Scores are summed  to give a maximum score of 8. 
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OBSERVATION AND RESULTS 
TABLE - 1 
AGE DISTRIBUTION OF BREAST CARCINOMA 
AGE (years) 
CASES 
NUMBER % 
21-30 2 2.7 
31-40 12 16.4 
41-50 27 37 
51-60 21 28.8 
61-70 7 9.6 
71-80 4 5.5 
TOTAL 73 100 
MEAN 50.18 
 
 Table 1 shows  the incidence of breast carcinoma in different age 
groups in our study. The youngest patient was 28 years old and the oldest 
patient was 80 years old. Maximum number of cases were seen in  41-50 
years age group. Mean age was 50.18 years. 80% of the cases were more 
than 40 years. 
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TABLE - 2 
MENSTRUAL STATUS IN BREAST CARCINOMAS 
MENSTRUAL 
STATUS 
NO. OF 
CASES % 
PREMENOPAUSAL 32 43.8 
POSTMENOPAUSAL 41 56.2 
 
 Table 6 shows number of cases in premenopausal and 
postmenopausal age groups. Majority of cases were postmenopausal. 
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TABLE - 3 
CLINICAL STAGEWISE DISTRIBUTION IN  
BREAST CARCINOMAS 
S.NO STAGE 
CASES 
NUMBER % 
1 1 6 8.2 
2 2 48 65.8 
3 3 19 26 
4 4 NIL NIL 
 
 Table 2 shows percentage of cases in each stage in our  
study. Maximum number of cases were stage 2. None of our cases were 
of stage 4. 
CHART - 3 
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TABLE -  4 
HISTOLOGICAL GRADEWISE DISTRIBUTION OF  
BREAST CARCINOMAS 
S.NO. GRADE 
CASES 
NUMBER % 
1 1 7 9.6 
2 2 53 72.6 
3 3 13 17.8 
 
 Table 3 shows percentage of cases in each grade. Maximum 
number of cases are grade 2. 
CHART - 4 
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TABLE - 5 
LYMPH NODE STAGEWISE DISTRIBUTION OF 
BREAST CARCINOMAS 
S.NO. LYMPH NODE STAGE 
CASES 
NUMBER % 
1 1 30 41.1 
2 2 25 34.2 
3 3 18 24.7 
 
 Table 4 shows percentage of cases in each lymph node stage. 
Maximum number of cases were in stage 1. 
CHART - 5 
LYMPH NODE STAGEWISE DISTRIBUTION OF 
BREAST CARCINOMAS 
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TABLE - 6 
NPI DISTRIBUTION IN BREAST CARCINOMAS 
S.NO. NPI 
CASES 
NUMBER % 
1 GOOD PROGNOSIS 5 6.9 
2 MODERATE PROGNOSIS 46 63 
3 POOR PROGNOSIS 22 30.1 
 
 Table 5 shows percentage of cases belonging to each group of NPI 
score. Majority of cases were having moderate prognosis. 
CHART - 6 
NPI DISTRIBUTION IN BREAST CARCINOMAS 
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TABLE - 7 
CORRELATION OF CLINICAL STAGING WITH NPI SCORE 
STAGE GOOD PROGNOSIS 
MODERATE 
PROGNOSIS 
POOR 
PROGNOSIS 
1 2 4 NIL 
2 2 38 9 
3 1 4 13 
4 NIL NIL NIL 
 
 Table 8 shows correlation between clinical staging and NPI score. 
There is statistically significant correlation between the two variables 
with a p value of 0.001. Majority of poor prognosis cases are of grade 3. 
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TABLE - 8 
ER, PR STATUS IN BREAST CARCINOMAS 
S.NO. ER,PR STATUS 
NO.OF 
CASES % 
1 ER+,PR+ 9 16.4 
2 ER+,PR- 8 14.5 
3 ER-,PR+ 5 9.1 
4 ER-,PR- 33 60 
 
 Table 7 shows ER,PR status in breast carcinomas.16.4% were 
positive for both. 14.5% were ER positive but PR negative. 9.1% cases 
were ER negative but PR positive. 60% of the cases were negative for 
both the receptors. ER positivity is seen in 30.9% of cases and PR 
positivity is seen in 25.5% of the cases. 
CHART - 8 
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TABLE - 9 
CORRELATION OF HISTOLOGICAL GRADING 
WITH ER, PR STATUS 
S.NO GRADE NO.OF CASES 
ER/PR + 
CASES 
1 1 7 6 
2 2 40 16 
3 3 8 2 
 
 Table 9 shows correlation between histological grading and ER, 
PR status. There is a statistically significant correlation between the two 
variables with a p value of 0.01.  
CHART - 9 
CORRELATION OF HISTOLOGICAL GRADING 
WITH ER, PR STATUS 
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TABLE - 10 
CORRELATION OF TUMOR SIZE WITH ER, PR STATUS 
S.NO TUMOR SIZE  (in cm) 
NO.OF 
CASES 
ER/PR+ 
CASES % 
1 1-2 10 5 50 
2 >2-5 39 16 41 
3 >5 3 1 33.3 
 
 Table 10 shows correlation between tumor size and ER, PR status.  
Percentage of ER/PR positivity decreases with increase in tumor size. 
TABLE - 11 
CORRELATION OF LYMPH NODE STAGE 
WITH ER, PR STATUS 
S.NO LYMPH NODE STAGE 
NO.OF 
CASES 
ER/PR + 
CASES 
1 1 24 7 
2 2 16 8 
3 3 15 7 
 
 Table 11 shows correlation between ER, PR status and lymph node 
stage. There is no statistically significant correlation between the two 
variables. 
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TABLE - 12 
CORRELATION OF CLINICAL STAGING 
WITH ER, PR STATUS 
S.NO STAGE NO.OF CASES 
ER/PR+ 
CASES 
1 1 5 2 
2 2 38 14 
3 3 12 6 
4 4 NIL NIL 
 
 Table 12 shows correlation between ER, PR status and clinical 
stage. There is no statistically significant correlation between the two 
variables. 
TABLE - 13 
CORRELATION OF NPI SCORE WITH ER, PR STATUS 
S.NO. NPI NO.OF CASES ER/PR+ 
1 GOOD PROGNOSIS 3 2 
2 MODERATE PROGNOSIS 37 14 
3 POOR PROGNOSIS 15 6 
 
 Table 13 shows correlation between ER, PR status and NPI score. 
There is no statistically significant correlation between the two variables. 
 60
DISCUSSION 
 Incidence of breast carcinoma is increasing in India. Prognosis is 
related to a variety of clinical, pathological and molecular  features which 
include stage of the carcinoma, histologic type, grade and  lymph node 
metastasis. Estrogen and progesterone receptors, have with  increasing 
importance, influenced the management of this malignancy.  
AGE  DISTRIBUTION: 
 As  seen  in Table 1, mean age of  patients included  in our study  
was 50.18years. 80.9% of the cases were more than 40years of age.  
Maximum number of cases were in the age group of 41-50years. 
 This is less than the observation made by RhodesDT et al, who 
found more than 75% of the cases were above 50years and the mean age 
was 64 years(67). 
 But usually in Asian countries breast carcinoma occurs a decade  
earlier. Our results are in concordance with the study conducted by  
Lakmini.K.B.Mudduwa in which mean age was 52.5 years and  85.7%  of  
the patients were more than 40years. 
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MENSTRUAL  STATUS: 
 As shown in Table 6, 56.2% of the patients were postmenopausal  
women. This is in concordance with the study conducted by  
Louis.W.C.Chow et al, in which 52% of the women were  
postmenopausal(68) and Col V Dutta et al, in which 59% of the cases  
were postmenopausal women(69). 
HORMONE  RECEPTOR  STATUS  IN  BREAST CARCINOMAS: 
 The hormone receptor status of breast carcinoma can predict the  
response to adjuvant endocrine therapy.  
 In a study conducted by Priti Lal et al at NewYork with 3655  
breast carcinomas, ER was positive in 71.6% and PR in 47.4%(66). 
 Mehedad Nadji et al found in Miami with 5993 breast cancers ,that  
ER was positive in 75% of the cases and PR in 55% of the cases(74). 
 Li CI et al from Seattle conducted a  study between 1992 to 1998  
and found ER positivity in 77.5% and PR positivity in 67.7%(58). 
 These are some of the studies conducted in western population. 
 According to Lakhmini K.B.Mudduwa the prevelance of hormone  
receptor positive breast cancer in Asian countries has found to be lower  
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than western world where more than 50% tumors express hormone  
receptors(64). However the number of studies performed on this topic is  
much less in the Asian communities compared with the western world. 
 Ljiljana Hulpic et al conducted a study in Croatia with 242  cases  
and found ER positivity in 37.5%, PR positivity in 40.6% of the  
cases(47).   
 Azizun Nisa et al studied 150 cases in Karachi and found that  ER 
and PR was positive in 32.7% and 25.3% of the cases respectively(73). 
 In a study conducted by Desai SB et al in India of 798 cases ER  
was positive in 32.6% of the tumors and PR was positive in 46.1% of the  
cases(59). 
 Col V Dutta et al conducted a study in Army Hospital and  
Research centre in New Delhi and found that out of 75 cases, 24% were  
ER positive and 30% were PR positive(69). 
 In this study 40% of the cases were either ER or PR positive and  
60% of the cases are negative for both the receptors. ER is positive in  
30.9% of the cases and PR is positive in 25.5% of the cases. 
 These results are not in concordance with the studies conducted in 
western population.  
 63
 But the results of our study are in concordance with studies  
conducted in Asian  population and one study of western population . The 
overall positivity rate for ER  and PR  is  lower  possibly  because  of  the  
difference  in  techniques  of evaluation (70),  high  tumour  grades  and  
majority  being  menopausal women  in  our  study.  
 Nulliparity,  late age  at  first  birth,  early  age  at  menarche,  
higher body  mass  index and  the use of hormone replacement therapy  
have all been associated with increased risk of developing an ER +  
tumour but with a decreased risk of developing an ER- tumour.  Young 
patients have high levels of circulating oestrogens and a correspondingly 
low expression of steroid receptors, which is  reflected in their tumours. 
There  appears to be a variation in steroid  receptor positivity in the Asian 
population (69).  
CORRELATION OF HORMONE RECEPTOR POSITIVITY 
WITH OTHER PROGNOSTIC VARIABLES: 
 In this study there is a statistically significant association between 
ER, PR status and histological grade. Hormone receptor expression 
decreases with increasing tumor size but no statistically significant 
association between the two variables. No significant of ER, PR status 
with clinical staging, lymph node metastasis and NPI score noted. 
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 Lakmini.K.B.Mudduwa has found a significant inverse relation 
ship with the grade and ER, PR expression in his study. His study also 
shows no significant association of hormone receptor status with tumor 
size and lymph node metastases(64). 
 Ana Lucia Amaral Eisenberg et al in Brazil also has established a 
significant correlation between ER, PR status and histological grade(61). 
 Col.V.Dutta in India observed that the reactivity for steroid 
receptor decreases with increasing grade but no significant association 
with other variables like lymph node metastases, tumor size(69). 
 Ljiljana Hupic has found no statistically significant association 
between ER, PR status and NPI score in concordance with our study but 
in contrast to this study there is a significant association with lymph node 
metastases(47). 
 Kenneth McCarty and Rosemary.R.Millis et al have also obtained 
similar results of association between ER, PR status and histological 
grade but no association with other prognostic variables (71,72). 
 This study shows results of association between ER, PR status and 
other prognostic variables comparable to most of the studies conducted 
especially in Asian population. 
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SUMMARY AND CONCLUSION 
 73 cases of mastectomy specimens were received and clinical 
staging, histological grading and NPI score were analysed for these cases. 
55 cases were selected at random and ER, PR status was analysed using 
Quick score. 
 Greater than 80% of the cases were 40 years and above and 
majority were postmenopausal. Maximum number of cases were stage 2 
and grade 2 with majority having no lymph node metastases. 
              ER was positive in 30.9% and PR in 25.5%, as the prevalence of 
hormone receptor positive breast cancers is less in the study population of 
Asian women compared with western world. There was a statistically 
significant association between hormone receptor expression and 
histological grade but not with other prognostic factors. 
 Presence of hormone receptors correlates well with response to 
hormone therapy. There is a significant decrease in mortality and tumor 
recurrences with hormone therapy. So, determination of ER, PR status is 
essential in all cases irrespective of clinical staging and lymph node 
metastasis. 
MASTER CHART 
S. 
No. Bx. No. Age Menstrual Status 
Tumor 
size 
Lymph node 
stage Stage Grade NPI ER PR TUMOR TYPE 
1 1872/08 54 post menopausal 5 4 3A 2 6 negative negative IDC-NOS 
2 2162/08 38 pre menopausal 3 6 2B 2 5.6 negative negative IDC-NOS 
3 2206/08 50 pre menopausal 3 NIL 2A 2 3.6 negative negative IDC-NOS 
4 2374/08 50 post menopausal 7 4 3A 3 7.4 negative negative IDC-NOS 
5 2502/08 50 post menopausal 4 1 2B 2 4.8 negative negative IDC-NOS 
6 2579/08 60 post menopausal 4 3 2B 2 4.8 negative negative Mucinous CA 
7 2812/08 41 pre menopausal 4 NIL 2A 2 3.8 negative negative IDC-NOS 
8 3032/08 45 pre menopausal 2 NIL 1 2 3.4 negative negative IDC-NOS 
9 3069/08 55 post menopausal 3 NIL 2A 2 3.6 negative negative Mucinous CA 
10 3085/08 31 pre menopausal 4 9 3A 2 5.8 negative negative IDC-NOS 
11 3100/08 46 pre menopausal 4 NIL 2A 3 4.8 negative negative IDC-NOS 
12 3240/08 50 post menopausal 4 NIL 2A 2 3.8 negative negative IDC-NOS 
13 3594/08 53 post menopausal 5 NIL 2B 3 5 negative negative IDC-NOS 
14 3748/08 55 post menopausal 3 4 2B 2 5.6 negative negative IDC-NOS 
15 3926/08 50 pre menopausal 2.5 NIL 2A 2 3.5 negative negative IDC-NOS 
16 0012/09 53 post menopausal 5 4 3A 2 6 negative positive IDC-NOS 
17 56/09 28 pre menopausal 5 NIL 2B 2 4 negative negative IDC-NOS 
18 95/09 53 post menopausal 3 1 2A 2 4.6 negative negative IDC-NOS 
19 481/09 52 post menopausal 4 NIL 2A 2 3.8 negative negative IDC-NOS 
20 485/09 50 pre menopausal 5 2 3A 2 5 negative negative IDC-NOS 
21 562/09 43 pre menopausal 3 NIL 2B 2 3.6 positive negative IDC-NOS 
22 645/09 60 post menopausal 3 NIL 2A 1 2.6 positive negative Papillary CA 
23 659/09 34 pre menopausal 3 1 2B 1 3.6 negative positive IDC-NOS 
24 782/09 56 post menopausal 3 1 2B 2 4.6 negative negative IDC-NOS 
S. 
No. Bx. No. Age Menstrual Status 
Tumor 
size 
Lymph node 
stage Stage Grade NPI ER PR TUMOR TYPE 
25 1104/09 44 pre menopausal 5 2 3A 2 5 negative negative IDC-NOS 
26 1283/09 53 post menopausal 4 7 3A 2 5.8 positive negative IDC-NOS 
27 1301/09 45 pre menopausal 5 4 2B 2 6 positive positive IDC-NOS 
28 1329/09 57 post menopausal 7 4 3A 1 5.4 negative positive IDC-NOS 
29 1396/09 45 pre menopausal 3 3 2B 2 4.6 positive negative IDC-NOS 
30 1645/09 72 post menopausal 3 9 2A 2 5.6 negative negative IDC-NOS 
31 1731/09 46 pre menopausal 3 4 2B 2 5.6 negative negative IDC-NOS 
32 1788/09 75 post menopausal 3 NIL 2A 2 3.6 negative positive IDC-NOS 
33 1874/09 45 pre menopausal 2 3 2A 2 4.4 positive positive IDC-NOS 
34 1879/09 43 pre menopausal 6 2 3A 3 6.2 positive positive IDC-NOS 
35 1737/09 45 pre menopausal 2 3 2A 1 3.4 positive negative IDC-NOS 
36 1948/09 50 pre menopausal 7 NIL 2B 2 4.4 positive negative IDC-NOS 
37 2028/09 55 post menopausal 2 7 2A 2 5.4 negative positive IDC-NOS 
38 2037/09 80 post menopausal 5 4 3A 2 6 positive negative IDC-NOS 
39 2110/09 55 post menopausal 2 NIL 1 2 3.4 negative negative IDC-NOS 
40 2130/09 65 post menopausal 1 NIL 1 1 2.2 positive positive IDC-NOS 
41 2134/09 52 post menopausal 1 2 2A 1 3.2 negative negative IDC-NOS 
42 2154/09 65 post menopausal 8 NIL 2B 2 4.6 negative negative IDC-NOS 
43 2156/09 45 pre menopausal 2 3 2A 2 4.4 negative negative IDC-NOS 
44 2255/09 47 pre menopausal 8 2 3A 2 5.6   IDC-NOS 
45 2345/09 50 post menopausal 3 NIL 2A 3 4.6   IDC-NOS 
46 2347/09 50 post menopausal 5 5 3A 3 7 negative negative IDC-NOS 
47 2744/09 48 post menopausal 4 NIL 2A 2 3.8   IDC-NOS 
48 2490/09 52 post menopausal 1 NIL 1 2 3.2   IDC-NOS 
49 2558/09 45 post menopausal 4 1 2B 3 5.8   IDC-NOS 
50 2563/09 50 post menopausal 3 NIL 2A 2 3.6 negative negative IDC-NOS 
S. 
No. Bx. No. Age Menstrual Status 
Tumor 
size 
Lymph node 
stage Stage Grade NPI ER PR TUMOR TYPE 
51 2769/09 37 pre menopausal 4 2 2B 3 5.8   IDC-NOS 
52 2655/09 55 post menopausal 7 NIL 2B 2 4.4 negative negative IDC-NOS 
53 2791/09 55 post menopausal 3 NIL 3B 1 2.6   IDC-NOS 
54 2845/09 36 pre menopausal 4 1 2A 2 4.8 positive positive IDC-NOS 
55 0030/10 40 pre menopausal 4 1 2B 3 5.8 negative negative IDC-NOS 
56 43/10 35 pre menopausal 3 7 3A 3 6.6 positive positive IDC-NOS 
57 318/10 63 post menopausal 4 1 2B 2 4.8 positive positive IDC-NOS 
58 334/10 65 post menopausal 1.5 NIL 1 3 4.3 positive positive IDC-NOS 
59 487/10 30 pre menopausal 4 NIL 2A 2 3.8 positive positive IDC-NOS 
60 576/10 34 pre menopausal 3 NIL 2A 2 3.6 negative negative IDC-NOS 
61 896/10 34 pre menopausal 2 NIL 1 2 3.4 negative negative IDC-NOS 
62 1059/10 40 pre menopausal 3 1 2B 2 3.6 positive negative IDC-NOS 
63 1132/10 45 post menopausal 2 2 2A 2 4.4   IDC-NOS 
64 1172/10 75 post menopausal 8 5 3A 2 6.6   
IDC with 
Neuroendocrine 
Differentiation 
65 1286/10 55 post menopausal 5 4 3A 2 6   IDC-NOS 
66 1240/10 65 post menopausal 4 1 2B 2 4.8   IDC-NOS 
67 1286/10 55 post menopausal 5 4 3A 2 6   IDC-NOS 
68 1385/10 37 pre menopausal 7 NIL 3B 2 4.4   IDC-NOS 
69 1436/10 52 post menopausal 2 1 2A 2 4.4   IDC-NOS 
70 1449/10 36 pre menopausal 2 3 2A 3 5.4   IDC-NOS 
71 1471/10 70 post menopausal 2.5 NIL 2A 2 3.5   IDC-NOS 
72 1472/10 68 post menopausal 3 NIL 2A 2 3.6   IDC-NOS 
73 1648/10 45 pre menopausal 2.5 3 2B 3 5.5   IDC-NOS 
 
         
Fig.1 : 50/F, HARD PALPABLE MASS IN RIGHT BREAST  
INVOLVING ALL QUADRANTS AND SKIN INVOLVEMENT 
 
 
 
 
         
Fig.2 : 46/F, HARD PALPABLE MASS IN LEFT BREAST  
INVOLVING UPPER QUADRANT 
 
Fig. 3 : MRM SPECIMEN SHOWING A  
GROWTH MEASURING 4X3CM 
 
Fig. 4 : MRM SPECIMEN SHOWING A 
GROWTH MEASURING 5X4CM 
 
Fig. 5 : IDC-NOS, GRADE1, LOW POWER 
 
Fig. 6 : IDC-NOS, GRADE1, HIGH POWER 
 
Fig. 7 : IDC-NOS, GRADE2, LOW POWER 
 
Fig. 8 : IDC-NOS, GRADE2, HIGH POWER 
 
 
 
Fig. 9 : IDC-NOS, GRADE3, LOW POWER 
 
Fig. 10 : IDC-NOS, GRADE3, HIGH POWER 
 
Fig. 11 : MUCINOUS CARCINOMA, LOW POWER 
 
Fig. 12 : MUCINOUS CARCINOMA, HIGH POWER 
 
 
 
Fig. 13 : PAPILLARY CARCINOMA, LOW POWER 
 
Fig. 14 : PAPILLARY CARCINOMA, HIGH POWER 
 
Fig. 15 : IDC WITH NEUROENDOCRINE  
DIFFERENTIATION, LOW POWER 
 
Fig. 16 : IDC WITH NEUROENDOCRINE  
DIFFERENTIATION, HIGH POWER 
 
Fig. 17 : METASTATIC DEPOSIT IN LYMPH NODE, 
LOW POWER 
 
Fig. 18 : METASTATIC DEPOSIT IN LYMPH NODE, 
HIGH POWER 
 
Fig. 19 : IHC, ER POSITIVITY, LOW POWER 
 
Fig. 20 : IHC, ER POSITIVITY, HIGH POWER 
 
 
 
Fig. 21 : IHC, PR POSTIVITY, LOW POWER 
 
Fig. 22 : IHC, PR POSTIVITY, HIGH POWER 
MASTER CHART 
S. 
No. Bx. No. Age Menstrual Status 
Tumor 
size 
Lymph node 
stage Stage Grade NPI ER PR TUMOR TYPE 
1 1872/08 54 post menopausal 5 4 3A 2 6 negative negative IDC-NOS 
2 2162/08 38 pre menopausal 3 6 2B 2 5.6 negative negative IDC-NOS 
3 2206/08 50 pre menopausal 3 NIL 2A 2 3.6 negative negative IDC-NOS 
4 2374/08 50 post menopausal 7 4 3A 3 7.4 negative negative IDC-NOS 
5 2502/08 50 post menopausal 4 1 2B 2 4.8 negative negative IDC-NOS 
6 2579/08 60 post menopausal 4 3 2B 2 4.8 negative negative Mucinous CA 
7 2812/08 41 pre menopausal 4 NIL 2A 2 3.8 negative negative IDC-NOS 
8 3032/08 45 pre menopausal 2 NIL 1 2 3.4 negative negative IDC-NOS 
9 3069/08 55 post menopausal 3 NIL 2A 2 3.6 negative negative Mucinous CA 
10 3085/08 31 pre menopausal 4 9 3A 2 5.8 negative negative IDC-NOS 
11 3100/08 46 pre menopausal 4 NIL 2A 3 4.8 negative negative IDC-NOS 
12 3240/08 50 post menopausal 4 NIL 2A 2 3.8 negative negative IDC-NOS 
13 3594/08 53 post menopausal 5 NIL 2B 3 5 negative negative IDC-NOS 
14 3748/08 55 post menopausal 3 4 2B 2 5.6 negative negative IDC-NOS 
15 3926/08 50 pre menopausal 2.5 NIL 2A 2 3.5 negative negative IDC-NOS 
16 0012/09 53 post menopausal 5 4 3A 2 6 negative positive IDC-NOS 
17 56/09 28 pre menopausal 5 NIL 2B 2 4 negative negative IDC-NOS 
18 95/09 53 post menopausal 3 1 2A 2 4.6 negative negative IDC-NOS 
19 481/09 52 post menopausal 4 NIL 2A 2 3.8 negative negative IDC-NOS 
20 485/09 50 pre menopausal 5 2 3A 2 5 negative negative IDC-NOS 
21 562/09 43 pre menopausal 3 NIL 2B 2 3.6 positive negative IDC-NOS 
22 645/09 60 post menopausal 3 NIL 2A 1 2.6 positive negative Papillary CA 
23 659/09 34 pre menopausal 3 1 2B 1 3.6 negative positive IDC-NOS 
24 782/09 56 post menopausal 3 1 2B 2 4.6 negative negative IDC-NOS 
S. 
No. Bx. No. Age Menstrual Status 
Tumor 
size 
Lymph node 
stage Stage Grade NPI ER PR TUMOR TYPE 
25 1104/09 44 pre menopausal 5 2 3A 2 5 negative negative IDC-NOS 
26 1283/09 53 post menopausal 4 7 3A 2 5.8 positive negative IDC-NOS 
27 1301/09 45 pre menopausal 5 4 2B 2 6 positive positive IDC-NOS 
28 1329/09 57 post menopausal 7 4 3A 1 5.4 negative positive IDC-NOS 
29 1396/09 45 pre menopausal 3 3 2B 2 4.6 positive negative IDC-NOS 
30 1645/09 72 post menopausal 3 9 2A 2 5.6 negative negative IDC-NOS 
31 1731/09 46 pre menopausal 3 4 2B 2 5.6 negative negative IDC-NOS 
32 1788/09 75 post menopausal 3 NIL 2A 2 3.6 negative positive IDC-NOS 
33 1874/09 45 pre menopausal 2 3 2A 2 4.4 positive positive IDC-NOS 
34 1879/09 43 pre menopausal 6 2 3A 3 6.2 positive positive IDC-NOS 
35 1737/09 45 pre menopausal 2 3 2A 1 3.4 positive negative IDC-NOS 
36 1948/09 50 pre menopausal 7 NIL 2B 2 4.4 positive negative IDC-NOS 
37 2028/09 55 post menopausal 2 7 2A 2 5.4 negative positive IDC-NOS 
38 2037/09 80 post menopausal 5 4 3A 2 6 positive negative IDC-NOS 
39 2110/09 55 post menopausal 2 NIL 1 2 3.4 negative negative IDC-NOS 
40 2130/09 65 post menopausal 1 NIL 1 1 2.2 positive positive IDC-NOS 
41 2134/09 52 post menopausal 1 2 2A 1 3.2 negative negative IDC-NOS 
42 2154/09 65 post menopausal 8 NIL 2B 2 4.6 negative negative IDC-NOS 
43 2156/09 45 pre menopausal 2 3 2A 2 4.4 negative negative IDC-NOS 
44 2255/09 47 pre menopausal 8 2 3A 2 5.6   IDC-NOS 
45 2345/09 50 post menopausal 3 NIL 2A 3 4.6   IDC-NOS 
46 2347/09 50 post menopausal 5 5 3A 3 7 negative negative IDC-NOS 
47 2744/09 48 post menopausal 4 NIL 2A 2 3.8   IDC-NOS 
48 2490/09 52 post menopausal 1 NIL 1 2 3.2   IDC-NOS 
49 2558/09 45 post menopausal 4 1 2B 3 5.8   IDC-NOS 
50 2563/09 50 post menopausal 3 NIL 2A 2 3.6 negative negative IDC-NOS 
S. 
No. Bx. No. Age Menstrual Status 
Tumor 
size 
Lymph node 
stage Stage Grade NPI ER PR TUMOR TYPE 
51 2769/09 37 pre menopausal 4 2 2B 3 5.8   IDC-NOS 
52 2655/09 55 post menopausal 7 NIL 2B 2 4.4 negative negative IDC-NOS 
53 2791/09 55 post menopausal 3 NIL 3B 1 2.6   IDC-NOS 
54 2845/09 36 pre menopausal 4 1 2A 2 4.8 positive positive IDC-NOS 
55 0030/10 40 pre menopausal 4 1 2B 3 5.8 negative negative IDC-NOS 
56 43/10 35 pre menopausal 3 7 3A 3 6.6 positive positive IDC-NOS 
57 318/10 63 post menopausal 4 1 2B 2 4.8 positive positive IDC-NOS 
58 334/10 65 post menopausal 1.5 NIL 1 3 4.3 positive positive IDC-NOS 
59 487/10 30 pre menopausal 4 NIL 2A 2 3.8 positive positive IDC-NOS 
60 576/10 34 pre menopausal 3 NIL 2A 2 3.6 negative negative IDC-NOS 
61 896/10 34 pre menopausal 2 NIL 1 2 3.4 negative negative IDC-NOS 
62 1059/10 40 pre menopausal 3 1 2B 2 3.6 positive negative IDC-NOS 
63 1132/10 45 post menopausal 2 2 2A 2 4.4   IDC-NOS 
64 1172/10 75 post menopausal 8 5 3A 2 6.6   
IDC with 
Neuroendocrine 
Differentiation 
65 1286/10 55 post menopausal 5 4 3A 2 6   IDC-NOS 
66 1240/10 65 post menopausal 4 1 2B 2 4.8   IDC-NOS 
67 1286/10 55 post menopausal 5 4 3A 2 6   IDC-NOS 
68 1385/10 37 pre menopausal 7 NIL 3B 2 4.4   IDC-NOS 
69 1436/10 52 post menopausal 2 1 2A 2 4.4   IDC-NOS 
70 1449/10 36 pre menopausal 2 3 2A 3 5.4   IDC-NOS 
71 1471/10 70 post menopausal 2.5 NIL 2A 2 3.5   IDC-NOS 
72 1472/10 68 post menopausal 3 NIL 2A 2 3.6   IDC-NOS 
73 1648/10 45 pre menopausal 2.5 3 2B 3 5.5   IDC-NOS 
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ABBREVIATIONS 
 ER - Estrogen Receptor 
 PR - Progesterone Receptor 
 IDC-NOS - Invasive Ductal Carcinoma – Not Otherwise 
Specified 
 DCIS - Ductal Carcinoma In Situ 
 IHC - Immunohistochemistry 
 MRM - Modified Radical Mastectomy 
 CA - Carcinoma 
